{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:34:17Z","timestamp":1793082857026,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:00:00Z","timestamp":1778976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003500","name":"University of Padua","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.breast.2026.104819","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:32:11Z","timestamp":1779147131000},"page":"104819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Evolution of ER-cut-off definition in clinical trials for triple negative breast cancer: trends and patterns over 15 years"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8085-3170","authenticated-orcid":false,"given":"Giorgio","family":"Bonomi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Napetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8782-4509","authenticated-orcid":false,"given":"Gaia","family":"Griguolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Zangh\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7094-7986","authenticated-orcid":false,"given":"Fabio","family":"Girardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2622-0628","authenticated-orcid":false,"given":"Stefania","family":"Lando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4303-2462","authenticated-orcid":false,"given":"Giusy","family":"Landa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"La Commare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1390-4055","authenticated-orcid":false,"given":"Davide","family":"Massa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3967-9861","authenticated-orcid":false,"given":"Maria Vittoria","family":"Dieci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104819_bib1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.breast.2026.104819_bib2","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American society of clinical oncology\/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104819_bib3","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials","volume":"378","author":"Abe","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.breast.2026.104819_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-021-00308-7","article-title":"Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant\/adjuvant chemotherapy","volume":"7","author":"Dieci","year":"2021","journal-title":"Npj Breast Cancer"},{"key":"10.1016\/j.breast.2026.104819_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2024.100886","article-title":"Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort study","volume":"40","author":"Acs","year":"2024","journal-title":"The Lancet Regional Health - Europe"},{"key":"10.1016\/j.breast.2026.104819_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-022-00448-4","article-title":"Impact of low versus negative estrogen\/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer","volume":"8","author":"Yoder","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.breast.2026.104819_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100289","article-title":"The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis","volume":"6","author":"Paakkola","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104819_bib8","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/annonc\/mdx397","article-title":"Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer","volume":"28","author":"Fujii","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104819_bib9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejca.2021.02.020","article-title":"Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors e An analysis of 2765 patients from neoadjuvant clinical trials","volume":"148","author":"Villegas","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2026.104819_bib10","author":"Massa"},{"key":"10.1016\/j.breast.2026.104819_bib11","article-title":"Prognosis and biological characteristics of ER-Low metastatic breast cancer: results from a multicenter cohort and the TONIC trial","volume":"OF1\u201311","author":"Miglietta","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104819_bib12","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.2011.36.2574","article-title":"Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry","volume":"30","author":"Iwamoto","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104819_bib13","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104819_bib14","article-title":"The \u201clows\u201d: update on ER-low and HER2-low breast cancer. The breast","volume":"78","author":"Fusco","year":"2024","journal-title":"Official Journal of the European Society of Mastology"},{"issue":"1","key":"10.1016\/j.breast.2026.104819_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.breast.2026.104819_bib16","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.1999.17.5.1474","article-title":"Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer","volume":"17","author":"Harvey","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104819_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/02841869609098474","article-title":"Oestrogen receptor analysis of paraffin sections and cytosol samples of primary breast cancer in relation to outcome after adjuvant tamoxifen treatment","volume":"35","author":"Fern\u00f6","year":"1996","journal-title":"Acta Oncol (Madr)"},{"key":"10.1016\/j.breast.2026.104819_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/ajcp\/aqy028","article-title":"Low estrogen receptor (ER)-positive breast cancer and neoadjuvant systemic chemotherapy is response similar to typical ER-Positive or ER-Negative disease?","volume":"150","author":"Landmann","year":"2018","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.breast.2026.104819_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102511","article-title":"Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: an Italian consensus paper and critical review","volume":"114","author":"Miglietta","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2026.104819_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2025.105820","article-title":"Estrogen receptor-low positive breast cancer: historical perspective and recent advancements","volume":"162","author":"Zhang","year":"2025","journal-title":"Hum Pathol"},{"key":"10.1016\/j.breast.2026.104819_bib21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2026.104819_bib22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2026.104819_bib23","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104819_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101400","article-title":"211P ER-low breast cancer: evolution from primary tumor to relapse and prognostic impact","volume":"8","author":"Miglietta","year":"2023","journal-title":"ESMO Open"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:31:10Z","timestamp":1784928670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626001293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":24,"alternative-id":["S0960977626001293"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104819","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of ER-cut-off definition in clinical trials for triple negative breast cancer: trends and patterns over 15 years","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104819","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104819"}}